Septerna Inc SEPN
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-10-25 |
| Shares Out. | 45,080,000 |
| Website | septerna.com/ ↗ |
| Phone | 16503383533 |
| Employees | 130 |
| Revenue | $26.5M |
| Gross Profit | $26.5M |
| Net Income | -$8.6M |
| Free Cash Flow | $106.9M |
| Total Assets | $569.7M |
| Total Liabilities | $191.2M |
| Equity | $378.5M |
About Septerna Inc
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Septerna Inc is a publicly traded company under the ticker symbol SEPN on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)